PANORAMA 3 A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN in a randomized, 3-arm parallel design. This study will also assess the impact of administering s.c. BTZ (in combination with PAN and Dex) twice weekly for 4 cycles, and then weekly starting from Cycle 5 until disease progression in patients ≤ 75 years of age. Patients > 75 years of age will receive for the entire treatment period s.c. BTZ weekly (in combination with PAN and Dex) until disease progression.
Patients will be treated until disease progression or until they discontinue earlier due to unacceptable toxicity or for other reasons.
Patients who discontinued study treatment for reasons other than disease progression will be followed for efficacy every 6 weeks.
All patients will be followed for survival until the last patient entering long-term follow-up has completed a 3 year survival follow-up or discontinued earlier.
Key Inclusion Criteria:
Multiple myeloma as per IMWG 2014 definition
Requiring treatment for relapsed or relapsed/refractory disease
Measurable disease based on central protein assessment
1 to 3 prior lines of therapy
Prior IMiD exposure
Jason Lukas, M.D., Ph.D.
- Providence Regional Cancer Partnership - Everett